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Conclusions: In this work, we evaluated 6 atlas fusion methods for 
automated segmentation of lymph nodes in the 3-D head and neck CT 
images. Among all the methods, our recently proposed Markov 
Random Field (MRF) based fusion method that performs 
simultaneously both local weighted voting based fusion and smoothing 
(LWV+MRF) provided the best results, both in terms of overlap 
measure and contiguous regions. 
Source of Funding: Swiss National Science Foundation under Grant 
205321-124797  
 
PD-0476   
The potential role of diffusion-weighted MRI in tumour delineation 
of esophageal carcinoma 
F.M. Lever1, I.M. Lips1, O. Reerink1, A.L.H. van Lier1, C.A.T. van den 
Berg1, M.A. Moerland1, M. van Vulpen1, G.J. Meijer1 
1U.M.C. Utrecht, Radiation Oncology, Utrecht, The Netherlands  
 
Purpose/Objective: Delineation of esophageal tumours for 
radiotherapy treatment planning is currently done on CT images. 
Differentiating healthy tissue from tumour on CT is difficult due to 
poor soft tissue contrast. Thus, tumour delineation is predominantly 
based on identifying esophageal wall thickening. Determination of the 
tumour extent in the cranio-caudal (CC) direction remains particularly 
challenging. MRI with its various sequences can provide both 
anatomical and functional information. Diffusion-weighted MRI (DW-
MRI) makes it possible to identify areas with restricted diffusion, 
which occurs in many primary and metastatic tumors. This additional 
information may help to improve delineation of the treatment 
volume. The aim of this study is to assess the potential benefit of DW-
MRI in GTV delineation of esophageal tumours. 
Materials and Methods: Seven patients with esophageal cancer 
underwent a planning CT and an MRI scan. Scans were acquired within 
one week of each other. The MRI scan was performed on a 1.5T 
scanner and consisted of a diffusion-weighted MRI sequence (b = 800 
s/mm2) and T2w scans. Two physicians independently defined the GTV 
for each tumour: first on the CT images and then on the MR-images. 
The T2w images were used as anatomical images and were co-
registered to the DW-MRI scan. Consensus on the definition of CC 
tumour borders was evaluated by measuring the absolute difference 
between the delineations. Furthermore, inter-observer agreement 
was assessed using the conformity index (CI), defined as the ratio of 
common to encompassing volume. 
Results: The DW-MR images clearly showed areas of high contrast in 
the tumor region (fig. 1). Consequently the consensus on defining the 
caudal tumour border improved in 6 out of 7 patients when delineated 
on DW-MRI compared to CT. The median absolute difference between 
observers was 7mm on CT as opposed to 4mm on DW-MRI. Six out of 7 
caudal tumour borders were located near the gastro-esophageal 
junction (GEJ). Tumor delineation in this area is especially challenging 
with the CT-based delineations currently used in clinical practice. No 
difference was found in agreement on the cranial tumour border, with 
a median difference of 4mm between observers on both modalities. 
Delineations showed negligible disagreement in the transversal plane. 
This was also reflected in similar volumes delineated on CT and DW-
MRI (median: 59.7 vs. 58.3cm3). In this study with a small number of 
patients, the median CI showed no clear difference between 
modalities (CT: 0.77, range: 0.68-0.79 vs. DW-MRI: 0.75,range: 0.54-
0.84). However, an improvement in CI was seen in 5 out of 7patients 
on the DW-MRI based delineation. 
 
 
Conclusions: DW-MRI shows excellent contrast in esophageal tumours 
and consequently may be useful for esophageal tumour delineation. In 
comparison to CT-based delineations, our results demonstrate that 
DW-MRI is promising in defining tumour extent in the CC direction, 
especially in the caudal borders near the GEJ.  
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Purpose/Objective: In vivo dosimetry for intraoperative electron 
radiation therapy (IOERT) is challenging because of the non-reference 
conditions of the irradiated area. However, in vivo dosimetry is 
desirable for verification, recording and eventual correction of 
treatment. MOSFETs and radiochromic films have been used for these 
purposes, chiefly in breast treatments. The aim of our work is to share 
our first analysis on tumor bed absorbed dose evaluation regardless of 
its localization and begin a discussion on an action level (AL) for all 
treatments in general. 
Materials and Methods: Reinforced mobile MOSFETs model TN-
502RDM-H and Gafchromic MD-55-2 film were used. MOSFETs 
calibration involved a linear relationship between dose and voltage 
difference before and after irradiation. With regard to film 
calibration, polynomial fitting of the absorbed doses to the mean pixel 
values was performed. Associated uncertainties were also estimated. 
A general purpose LINAC was used for calibrations and treatments. 
Measurement uncertainties were assessed for both methods. 
Measurements were taken from 14 patients: 9 primary tumors (4 
rectal tumors, 2 breast, 1 abdominal sarcoma, 1 scapular sarcoma and 
1 lower limb skin tumor) and 5 relapses (3 presacral, 1 nodal and 1 
pancreatic recurrence) involving 15 pairs of measurements in total at 
the tumor bed. All data were normalized so that 100% corresponded to 
the maximum absorbed dose.  
Afterwards, two approaches to reviewing or compensating treatment 
involving AL were derived. They are formally equivalent, since AL = 
2u. In the first approach, u represents the uncertainty of a single 
measurement. However, in the second, u represents the mean 
standard error (MSE) of a series of measurements. AL should be added 
to the intended absorbed doses interval (e.g. 90%-100%). 
Results: The three identified sources of uncertainty of the measured 
absorbed dose were those associated with beam calibration, equal to 
0.4%, lack of linearity of linac output (e.g. 0.03 Gy in a typical 3000 
MU treatment) and detector response, totalling 1.7% in the case of 
MOSFETs and 2.4% in the case of films (1 SD). 
Descriptive statistics of our data are depicted in table 1. The two 
distributions (fig. 1) did not appear as significantly shifted when 
subjected to the Wilcoxon signed ranks test (p = 0.363). 
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normalized absorbed doses (%) MOSFET film 
mean 95.0 96.4 
standard dev. 5.4 5.0 
u (MSE) 1.4 1.3 
2u (2 MSE) 2.8 2.6 
Table 1. Descriptive statistics of the in vivo data 
 
 Fig. 1. 
The uncertainty given for a single measurement based solely on 
detector and linac factors is greater and leads to a more conservative 
AL, whereas the AL derived from the MSE accounts for the variability 
involved in the whole procedure. 
Conclusions: An AL could be established after a thorough evaluation 
of the uncertainties associated with the in vivo dosimetry method 
employed. When added to the intended absorbed doses interval, this 
leads to non-action intervals (e.g. 85%-105% or 87%-103%, from our 
data and examples). As seen, these AL would remain coherent with in 
vivo dosimetry breast results already published and could be an initial 
proposal for future intervention protocols. 
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Purpose/Objective: Breast conserving therapy with complementary 
radiotherapy is an effective alternative for mastectomy; randomized 
trials in 20-years observations confirmed the comparable survivals in 
women treated with BCT and mastectomy. Standard procedure after 
BCT is whole breast irradiation (which reduces local risk of recurrence 
in about 16-30%) with higher dose on tumour bed (it decreases the risk 
of recurrence by 6%) for 5-7 weeks. The dose escalation may be 
proceeded by interstitial and cavital brachytherapy, intraoperative 
radiotherapy and conformal RT (3D-CRT) from external beams.  
In this study IORT was the only method used to boost the tumour bed. 
The aim of the study was to evaluate effectiveness of treatment, 
analyse early and late radiation reactions, cosmetic effect and quality 
of patients life.  
Materials and Methods: There were analysed 150 patients after BCT, 
IORT (10Gy/1 fraction; electron beam) and EBRT (50Gy/25 fractions; 
two tangential photon beams) with minimal observation period of 1 
year. The clinical profile is presented in table below. 
 
Tab.1  
Tumour size Number of 
pts. 
Tis 9 
T1mi 1 
T1a 1 
T1b 45 
T1c 79 
T2 15 
T3 0 
T4 0 
Histopatology Number of pts.
ductal invasive 71 
lobular invasive 2 
ductal invasive+DCIS 52 
lobular invasive+LCIS 1 
DCIS 8 
LCIS 0 
mucinous, apocrinal, tubular 16 
Patients number with feature N+: 25. 
 
During observation after IORTand in 1st, 6th, 12th, 24th and 36th 
month after EBRT we made: 
l physical examination,  
l photos of the breast,  
l analysis of acute and late toxicity.  
Patients filled in the quality of live questionnaires (QLQ-C30 and QLQ-
BR23) with the same frequency as observation schedule. 
Six months after EBRT mammography with ultrasounds of the breast 
was made in all patients.  
Results: No local recurrence occurred during observation period. 
Acute skin reactions in grade 1 and 2 were observed in 21,2% of 
patients, although therewere no acute and late toxicities both in 
grade 3 and 4. The cosmetic outcome according to the physical 
examination and photos analysis was good to excellent in 81,5% of 
patients. Pain in breast was observed in 20,6 % patients and 
hyperesthesia of the skin in 17,0 % patients. 
The edema of breast was reported by 81,3 % of patients after 1 
month, 63,4% after 6 months, 54,9 % after 1 year and 56% after 2 
years fromend of RT. The colour of breast skin has changed in 67,8 % 
of patients after 1 month, 44,1 % after 6 months, 37,8 % after 1 year, 
31% after 2 years from the end of RT. 
Conclusions: There was no local recurrences. IORT with EBRT was 
well tolerated, with no severe acute and late toxicities of the skin. 
The external beam course afterwards was shortenedby 1 week. After 
tumor resection the tumor bed can be precisely covered by the 
homogenous electron beam with no geographical mistake.  
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Purpose/Objective: Two randomized trials (Eliot; Targit) are showing 
encouraging data in favour of breast IORT in the field of partial breast 
irradiation. We present a new breast applicator to optimize the dose 
delivery with IORT using 50 kV X ray brachytherapy (XRB). 
Materials and Methods: In order to mimic the mamosite ® and 
intrabeam® applicator we developed an applicator to achieve the 
following characteristics: homogeneous dose at the surface of a 
spheric volume; protection of the skin overlying the surgical incision; 
good fixation and coaptation of the breast tissues of the tumor bed to 
the applicator; possible shielding of some tissues at risk (chest wall, 
lung); short treatment time and easy radioprotection. Between 2010 
and 2012 a series of dummy spherical applicators were tested with 
two breast surgeons to create the optimal sizes, shapes, fixation and 
shielding devices. A series of hollow nylon made applicators were then 
produced using a rapid prototyping procedure. These applicators were 
tested in sham irradiation with patients using the Papillon system 
(Ariane Medical systems™) delivering 50 kVp X-Rays. The dose 
distribution was measured and calculated with ion chamber, 
gafchromic films and a dedicated TPS with Monte Carlo algorythm 
(MC2Plan®). An international patent was given to the NBA. 
Results: Applicators between 3 and 6 cm diameter were tested 
(figure). The dose uniformity was excellent (± 4%) at the surface of 
the 310 ° spherical NBA (the isotropic X Ray source being in the center 
of the NBA). The percentage depth dose was in average (depending on 
the diameter of the NBA) 60% (of the surface dose) at 5 mm and 40% 
at 1cm. The eyelet positioned on the rim of the NBA made the fixation 
stable and the rim with the 310° beam resulted in a good protection 
of the overlying skin on the 'north pole' of the NBA. Thanks to forced 
cooling of the X ray tube anode, the Papillon system ® can deliver a 
typical 20 Gy treatment in 2 to 3 minutes. A flexible lead apron 
positioned at the surface of the patient during treatment made the 
radioprotection simple (medical and paramedical staff can stay in the 
OR during irradiation behind screen if needed). The first clinical 
results will be presented at the time of the meeting. 
Conclusions: The NBA used with the Papillon system provides a good 
dose distribution into the breast tumor bed after local excision. The 
easy and accurate positioning by the surgeon, the very short 
